Adjuvant therapy of pancreatic cancer: Highlights from the "2013 ASCO gastrointestinal cancers symposium". San Francisco, CA, USA. january 24-26, 2013

Journal of the Pancreas

Volumn 14, Issue 2, 2013, Pages 119-122

  Chaulagain, Chakra P ^a   Ng, John ^b   Goodman, Martin D ^a   Saif, Muhammad Wasif ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b New York Presbyterian Hospital ^*  (United States)

Author keywords

Chemotherapy, adjuvant; Erlotinib; Pancreatic Neoplasms; S 1 (combination)

Indexed keywords

CAPECITABINE; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTINUOUS INFUSION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; LEUKOPENIA; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS METASTASIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOSPHORYLATION; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; DRUG COMBINATIONS; HUMANS; MODELS, BIOLOGICAL; OXONIC ACID; PANCREATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TEGAFUR;

EID: 84875049897     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Neoptolemos JP, Stocken DD, Friess H, Bassi C et. al. A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer. N Engl J Med 2004;350:1200-10.
2. Oettle H, Post S, Neuhaus P, Gellert K et al. Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer. A Randomized Controlled Trial. JAMA. 2007;297:267-277
3. Neuhaus P, Riess H, Post S, Gellert K et al. CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol 26: 2008 (May 20 suppl; abstr LBA4504).
4. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P. Adjuvant Chemotherapy with Fluorouracil plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection. A Randomized Controlled Trial. JAMA. 0;0(10):1073-1081
5. Regine WF, Winter KA, Abrams RA, Safran H et al. Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma: A randomized Controlled Trial. JAMA. 2008;299(9):1019-1026.
6. Uesaka K, Fukutomi A, Boku N, Kanemoto H et al. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study). J Clin Oncol 30: 2012 (suppl 34; abstr 145).
7. Fan KY, Wild AT, Laheru DA, Pawlik TM. Phase II study of erlotinib combined with adjuvant chemoradiation and chemotherapy for resectable pancreatic cancer. J Clin Oncol 30: 2012 (suppl 34; abstr 269).
8. Saif MW, Syrigos KN, Katirtzoglou NA. S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs. 2009 Mar; 18(3):335-48.
9. Ioka T, Ikeda M, Ohkawa S, Yanagimoto H et al. Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study. J Clin Oncol 29: 2011 (suppl; abstr 4007)
10. Park SR, Park MS, Park YL, Kim NK et. al. CYP2A6 genetic polymorphism as a predictive marker for clinical outcomes in patients (pts) with metastastic gastric carcinoma (MGC) treated with S-1 plus docetaxel. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 4633